These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1243595)

  • 1. HL-A antigens in Japanese Patients with Graves' disease.
    Grumet FC; Payne RO; Konishi J; Mori T; Kriss JP
    Tissue Antigens; 1975 Nov; 6(5):347-52. PubMed ID: 1243595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Human leukocyte antigen (HLA) complex and anti-thyroidal antibodies in Graves' disease].
    Lacka K; Kordel M; Gembicki M
    Pol Tyg Lek; 1989 Feb 13-20; 44(7-8):179-81. PubMed ID: 2682567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA antigens in Japanese patients with Graves' disease and Hashimoto's disease [proceedings].
    Konishi J; Grumet FC; Payne RO; Mori T; Kriss JP
    Diabete Metab; 1976 Sep; 2(3):163-4. PubMed ID: 1036991
    [No Abstract]   [Full Text] [Related]  

  • 4. Peripheral blood T lymphocyte sensitization to thyroid microsomal antigen from patients with Graves' disease negative for circulating anti-thyroid microsomal antibodies.
    Matsubayashi S; Sakatsume Y; Kasuga Y; Akasu F; Tamai H; Volpé R
    Clin Invest Med; 1990 Dec; 13(6):339-42. PubMed ID: 2078913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of the HL-A system in Basedow's disease (author's transl)].
    Jaffiol C; Seignalet J; Baldet L; Robin M; Lapinski H; Mirouze J
    Ann Endocrinol (Paris); 1976; 37(2):111-2. PubMed ID: 1036872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The decrease in non-specific suppressor T lymphocytes in female hyperthyroid Graves' disease is secondary to the hyperthyroidism.
    Gerstein HC; Rastogi B; Iwatani Y; Iitaka M; Row VV; Volpé R
    Clin Invest Med; 1987 Jul; 10(4):337-44. PubMed ID: 2888555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of MHC and Gm in liability to autoimmune thyroid disease.
    Nagataki S
    Mol Biol Med; 1986 Feb; 3(1):73-84. PubMed ID: 3007922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M; Hussain M; Cundy T; Vergani D
    J Clin Lab Immunol; 1989 Sep; 30(1):1-5. PubMed ID: 2577115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.
    Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroglobulin antibodies in Graves' disease are associated with T-cell receptor beta chain and major histocompatibility complex loci.
    Demaine AG; Ratanachaiyavong S; Pope R; Ewins D; Millward BA; McGregor AM
    Clin Exp Immunol; 1989 Jul; 77(1):21-4. PubMed ID: 2569950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese.
    Kamizono S; Hiromatsu Y; Seki N; Bednarczuk T; Matsumoto H; Kimura A; Itoh K
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):759-64. PubMed ID: 10848881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of HLA antigens in the manifestation and course of Graves' disease.
    Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of possible antiidiotypic control mechanisms in Graves' disease.
    Moynier M; Montano J; Williams RC; Pathak D; DeGroot LC; Hill BL; Marshall NJ
    J Lab Clin Med; 1988 Jul; 112(1):99-108. PubMed ID: 2839588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Graves' disease. Predominance of the DRw3 antigen (author's transl)].
    Allanic H; Fauchet R; Lorcy Y; Heim J; Guéguen M; Leguerrier AM; Genetet B
    Nouv Presse Med; 1980 Jun; 9(26):1823-6. PubMed ID: 6893077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histocompatibility antigens in Graves' disease.
    Ford D; Knight JG; Reeve JK; Stewart RD
    Aust N Z J Med; 1976 Aug; 6(4):297-9. PubMed ID: 1070984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the fourth component of complement in Graves' disease and type I diabetes mellitus.
    Skanes V; Larsen B; Sampson-Murphy L; Farid NR
    Clin Invest Med; 1985; 8(2):126-32. PubMed ID: 3869086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HL-A in Graves' disease and in diabetes mellitus insulin-dependent.
    Seignalet J; Mirouze J; Jaffiol C; Selam JL; Lapinski H
    Tissue Antigens; 1975 Oct; 6(4):272-4. PubMed ID: 1242826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.